Deutsche Bank
XERS icon

Deutsche Bank’s Xeris Biopharma Holdings XERS Stock Holding History

Deutsche Bank’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.61M Sell
623,012
-317,580
-34% -$2.11M ﹤0.01% 1461
2025
Q4 		$7.38M Sell
940,592
-627,053
-40% -$4.94M ﹤0.01% 1172
2025
Q3 		$12.8M Buy
1,567,645
+830,718
+113% +$5.52M ﹤0.01% 985
2025
Q2 		$3.44M Sell
736,927
-19,480
-3% -$89.3K ﹤0.01% 1419
2025
Q1 		$4.15M Buy
756,407
+628,807
+493% +$2.54M ﹤0.01% 1335
2024
Q4 		$433K Buy
127,600
+48,068
+60% +$155K ﹤0.01% 2684
2024
Q3 		$227K Buy
79,532
+24,231
+44% +$62.2K ﹤0.01% 2870
2024
Q2 		$124K Sell
55,301
-13,242
-19% -$26.7K ﹤0.01% 3042
2024
Q1 		$151K Buy
68,543
+2,464
+4% +$6.38K ﹤0.01% 2974
2023
Q4 		$155K Sell
66,079
-2,002
-3% -$3.69K ﹤0.01% 3006
2023
Q3 		$127K Buy
68,081
+10,203
+18% +$23.4K ﹤0.01% 3051
2023
Q2 		$152K Sell
57,878
-30,977
-35% -$78.9K ﹤0.01% 3042
2023
Q1 		$145K Buy
88,855
+30,231
+52% +$37.8K ﹤0.01% 3163
2022
Q4 		$78K Buy
58,624
+883
+2% +$1.25K ﹤0.01% 3437
2022
Q3 		$90K Sell
57,741
-8,839
-13% -$14.6K ﹤0.01% 3374
2022
Q2 		$102K Buy
+66,580
New +$140K ﹤0.01% 3516
2021
Q2 		– Sell
-99,860
Closed -$451K – 4824
2021
Q1 		$451K Buy
99,860
+64,829
+185% +$350K ﹤0.01% 3166
2020
Q4 		$172K Buy
35,031
+9,259
+36% +$46.3K ﹤0.01% 3549
2020
Q3 		$153K Buy
25,772
+5,857
+29% +$23.4K ﹤0.01% 3349
2020
Q2 		$53K Buy
19,915
+6,298
+46% +$21.9K ﹤0.01% 3791
2020
Q1 		$27K Buy
13,617
+3,942
+41% +$17K ﹤0.01% 3825
2019
Q4 		$67K Buy
9,675
+2,136
+28% +$17.6K ﹤0.01% 3802
2019
Q3 		$73K Sell
7,539
-12,682
-63% -$143K ﹤0.01% 3732
2019
Q2 		$229K Sell
20,221
-14,357
-42% -$151K ﹤0.01% 3740
2019
Q1 		$346K Buy
34,578
+27,874
+416% +$357K ﹤0.01% 3673
2018
Q4 		$112K Sell
6,704
-8,312
-55% -$167K ﹤0.01% 4168
2018
Q3 		$263K Buy
+15,016
New +$326K ﹤0.01% 4109

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank's XERS Position: Q1 2026 in Review

Deutsche Bank reduced its Xeris Biopharma Holdings (XERS) stake by 34% in Q1 2026, selling an estimated $2.11M and leaving 623,012 shares worth $3.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1461.

Deutsche Bank first reported a position in XERS in Q3 2018 and has held it in 27 quarters since. The position peaked at $12.8M in Q3 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Deutsche Bank held 623,012 shares of Xeris Biopharma Holdings worth $3.61M as of Q1 2026.
  • Deutsche Bank sold 317,580 Xeris Biopharma Holdings shares in Q1 2026, an estimated $2.11M.
  • Xeris Biopharma Holdings made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1461 holding.
  • Deutsche Bank first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 27 quarters since.
  • Deutsche Bank's Xeris Biopharma Holdings position peaked at $12.8M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.